The Baldwin Group $7.7 Billion Take-Private: Deal Terms, Valuation and Strategic Analysis

Baldwin disclosed a $7.7 billion enterprise value built from a $4.6 billion equity purchase price and $3.1 billion of net debt, with $32.50 in cash for each Class A share.

Enterprise value, equity value and net debt

The 14 September company announcement and the accompanying Form 8-K confirm the bridge: approximately $4.6 billion of equity value plus approximately $3.1 billion of net debt assumed or refinanced equals the stated $7.7 billion enterprise value.^[2][4] Net debt is 40.3% of enterprise value. That arithmetic is an Acquiry calculation from disclosed inputs, not a sources-and-uses statement.^[22] It is also not a substitute for a closing funds-flow. Rollover elections, TRA settlement and any refinancing of existing facilities will change the cash that actually moves at close even if the published enterprise-value identity stays intact.

The equity purchase price is the cash-equity headline before rollover elections. Because eligible colleagues may keep a significant minority, the $4.6 billion figure is not a simple “all equity cashed out” number. It is the published equity value of the take-private. Square Acquisition Parent, owned by Sequence AI Holdings, Inc., is the merger parent named in the 8-K, with two merger subsidiaries used to collapse Baldwin’s public-company and OpCo structure. Baldwin’s board process included an independent special committee advised by Centerview and Wachtell Lipton.^[4][2]

The legal architecture matters because Baldwin is an Up-C: the listed company owns a controlling interest in an operating partnership while pre-IPO members hold OpCo units and paired Class B shares. At 20 February 2026 the 10-K recorded 96.7 million Class A shares and 46.1 million Class B shares outstanding. Under the filed mechanics, Class A shares receive the cash price. Class B shares are cancelled for no separate cash consideration because their economics sit with associated OpCo units, which are cashed out, retained or rolled under the merger and support agreements. Any summary that says every Baldwin security receives identical cash misses that distinction.^[5][18]

Cash consideration and premium

Holders of Baldwin Class A common stock receive $32.50 per share in cash. The merger agreement treats Class B shares and associated OpCo units separately, so it is inaccurate to describe every security as receiving identical cash. Baldwin’s Up-C architecture, documented in the 2025 Form 10-K, is why that distinction exists: public Class A stock sits beside OpCo units and Class B high-vote stock.^[5][18] Baldwin states an approximately 88% premium to the unaffected 17 June 2026 close. Structured market data shows a $17.33 close that day, which produces 87.5% by direct division — consistent with the company’s rounding.^[2][21][22]

Relative to the 11 September close of $29.65, the cash price is a 9.6% premium. That is the residual gap after the stock had already moved during the rumoured period. The 88% figure is the company’s chosen unaffected reference, not the last close before the 8-K.^[21][22] Using the unaffected date is standard when a stock has already begun to price a transaction. It is also the figure Baldwin chose to publish. This article reports both the unaffected premium and the last-close residual so readers can see the path, not so they can average them into a third number.

BWIN closed at $29.65 on 11 September, $32.00 on announcement day and $32.49 on 15 September, one cent below the offer. The near-zero spread is a market observation, not a closing-probability estimate.^[21] Spreads can stay tight for reasons that have nothing to do with regulatory odds: index reconstitution, short covering, or simply a cash deal with committed financing. This article does not convert the one-cent gap into a probability.

Ownership and rollover

The transaction is a majority recapitalization, not an all-cash freeze-out of every holder. Eligible Baldwin colleagues may roll equity and retain a significant minority stake. The public form of the rollover agreement leaves holder-specific schedules blank, so the exact percentage is not in the filing.^[4][19] Baldwin presents broad colleague ownership as a defining cultural element; the take-private is designed to keep that principle for eligible employees rather than cash them all out. DFO and Sequence acquire control. Continuing holders accept private valuation, transfer and exit constraints that the public form agreement does not describe in full. Public Class A holders receive liquidity at the offer. They do not retain upside beyond that cash price.

A Tax Receivable Agreement amendment caps final TRA payments at $298,450,598 and then terminates the agreement. That is a known cash use at close. Its funding treatment relative to the published equity value is not isolated in the public exhibits.^[18][20]

Deal protections

The merger agreement provides a $170.334 million company termination fee (3.70% of equity value) for specified superior-proposal and recommendation-change circumstances, and a $276.218 million parent termination fee (6.00% of equity value) for specified parent breach or failure-to-close scenarios. The 1.62x ratio between parent and company fees allocates more financial consequence to buyer failure. That is consistent with a transaction dependent on a private acquisition vehicle and committed financing, while preserving Baldwin’s fiduciary out for an unsolicited superior proposal before the shareholder vote.^[5][22] A fiduciary out is not a second bidder. It is a contractual path if one appears before the vote. No competing proposal is in the public record reviewed for this article.

The initial outside date is 14 June 2027. It automatically extends to 14 September 2027 if specified regulatory conditions remain outstanding while other conditions are satisfied or waived. The contract therefore treats regulatory timing, not financing availability, as the likely source of long-stop delay. Buyer financial advisers are J.P. Morgan and Goldman Sachs; the independent special committee used Centerview and Wachtell Lipton; Baldwin used Piper Sandler and Freshfields.^[2][5] Those names establish process, not outcome. A special committee and two bulge-bracket buyer banks do not make a closing date certain. They make the record of how the board got to a signed merger agreement.

Class A shareholders receive a defined cash exit. Sequence secures a scaled US insurance distribution platform on which to apply Atlas. Competing consolidators face a privately controlled peer with patient capital and no conventional fund expiry. Eligible colleagues who roll keep economic participation and give up public-market liquidity. Those are structural consequences of the filed terms, not a ranking of winners.^[2][3] The take-private reallocates who bears operating risk after close. It does not, by itself, change whether CAC integration lands or whether organic production recovers. Those two operating questions sit in the financial baseline and the closing section; they are not restated as a second verdict here.

Baldwin entered the take-private as a $1.5 billion-revenue distributor whose Q2 headline growth of 30% ran far ahead of 2% organic growth, with Adjusted EBITDA margin at 23.7%.

The Baldwin Group is a Tampa-based US insurance distributor built through organic production and serial acquisition. It distributes commercial and personal insurance, employee benefits, specialty products, reinsurance and risk-capital solutions, and reports serving more than three million clients. The 2025 Form 10-K describes an Up-C holding structure and a colleague-ownership culture that the take-private is designed to extend rather than unwind.^[18] The attraction is a combination of recurring renewal economics, trusted producer relationships, carrier access, proprietary client and risk data, and regulatory standing that is slow to reproduce. Sequence and DFO are buying that distribution franchise, not a balance-sheet arb.

The asset is not capital-light in the simple sense once acquisition debt is included. The operating model generates commissions, fees and cash, but Baldwin has compounded through M&A and entered 2026 with a large CAC transaction still integrating. This take-private therefore buys both a distribution network and an active transformation programme.

Revenue, Adjusted EBITDA, margins and cash

FY2025 revenue was $1.5 billion, up 8%. Adjusted EBITDA was $341.5 million, up 9%. Adjusted free cash flow was $87.2 million — 25.5% conversion of Adjusted EBITDA, an Acquiry calculation from company-defined non-GAAP measures ($87.2m ÷ $341.5m).^[7][22] H1 2026 revenue exceeded $1.0 billion and Adjusted EBITDA reached $254.0 million after CAC Group joined. H1 adjusted free cash flow was $46.2 million.^[6]

Q2 2026 revenue was $492.9 million, up 30%. Adjusted EBITDA was $116.7 million, up 37%, and margin expanded 110 basis points to 23.7%. Adjusted free cash flow in the quarter was $46.4 million. Those are the operating facts the take-private is written against: a scaled distributor with expanding non-GAAP margin and modest cash conversion relative to Adjusted EBITDA. Cash conversion is the harder underwriting line. A buyer can live with 23.7% Adjusted EBITDA margin if free cash flow later tracks earnings. If conversion stays near a quarter of Adjusted EBITDA while leverage is material, the credit conversation becomes the operating one.^[6]

Client count is a company-reported operating statistic, not a revenue-quality metric. Scale is why Sequence can talk about workflow redesign as an enterprise programme rather than a departmental pilot.^[2] Three million clients, a multi-line product set and a producer network that has already absorbed CAC are the operating surface the take-private inherits. They are also the reason integration sequencing matters more than a slogan about AI.

Reported growth versus organic growth

Company-defined organic revenue growth in Q2 was 2%. CAC Group revenue grew 23% on the comparison Baldwin provides. The gap to the 30% headline rate is the quality-of-growth issue, not an accounting error: acquired contribution, including CAC after the Q1 2026 combination, is doing substantial work in the reported result.^[6][8] Baldwin’s organic definition excludes the contribution of acquisitions and divestitures in the manner the company discloses in its earnings materials. This article uses that company definition rather than reconstructing an alternative organic series.

That 2% print does not make the franchise weak. It does mean the take-private is being underwritten on a business whose recent organic engine is running well below the printed growth rate. A full entry multiple can be supported by durable organic growth, margin expansion, accretive consolidation and deleveraging. If growth remains acquisition-dependent, the capital requirement and integration burden stay high. If organic production accelerates while CAC synergies land, the entry multiple compresses faster. Atlas and private ownership have to do more of the work that acquisitions have been doing in the headline. The quality-of-growth question is therefore not whether Baldwin can report 30% again. It is whether organic production, producer retention and CAC synergy delivery can carry a private capital structure without another large acquisition to refill the print.

CAC contribution and non-GAAP language

Baldwin completed the CAC Group combination in Q1 2026 after announcing it in December 2025. The combination was presented as creating the largest majority employee-owned insurance distributor of its type. Disclosed consideration included a $1.026 billion upfront price, up to $250 million of earnout and a $70 million deferred payment, with expectations of more than $2 billion of 2026 revenue and more than $470 million of Adjusted EBITDA, at a 7.9x synergy-inclusive multiple on expected 2025E pro forma Adjusted EBITDA.^[8] The take-private therefore arrives during a live integration, not after it has been fully digested. Management capacity is a scarce input: CAC systems, producer alignment and now an Atlas programme will overlap.

Adjusted EBITDA and adjusted free cash flow are Baldwin-defined non-GAAP measures. The published take-private multiple uses the company’s trailing Adjusted EBITDA figure. This article does not substitute a GAAP operating-profit multiple, and it does not restate that multiple as a synergy-adjusted print. Readers should keep the label attached to the number.

Specific transaction metrics including the post-close debt maturity schedules, exact employee rollover percentages, and discrete technology deployment budgets remain contractually private.

The disclosed strategy is private ownership to fund AI-enabled workflow redesign, talent and colleague ownership. Sequence’s Atlas platform and the BankSouth reference are evidence of method, not a quantified Baldwin synergy case.

What has been disclosed

Baldwin says strategy, leadership and culture remain in place. Private ownership is intended to support longer-duration investment in AI-enabled workflow redesign, recruiting and broader colleague ownership.^[2][9] Trevor Baldwin wrote that he has “never been more convinced of a path than I am of this one,” and that it is possible, perhaps likely, that Baldwin could be public again one day — without committing a relisting.^[9] His stakeholder letter frames AI as capacity creation: less gathering, rekeying, reconciling and chasing, so advisers and underwriters spend more time on judgment and relationships. It also identifies predictive pricing, claims analytics, appetite matching, proprietary product development and faster claims service as longer-term opportunities. That framing is commercially sound. In insurance distribution, blunt labor removal can destroy the client and carrier relationships that generate renewal revenue.^[9]

Sequence, in “Built to Refound,” describes itself as a permanent holding company with an engineering-led operating model and a proprietary platform called Atlas, and says it will work beside Baldwin’s operators rather than drop in point tools.^[10] DFO is identified as Michael Dell’s family investment office, supplying patient capital without a conventional fund expiry.^[3][2] The disclosed intention is therefore three-layered: keep Baldwin’s operators, give them a longer clock than the public market, and apply Sequence’s engineering bench to insurance workflows. That is the strategic thesis in the primary documents. It is not a quantified cost-save programme and it is not a disclosed AI budget. Label the claims: Baldwin and Sequence have disclosed the operating intention; BankSouth is reference-case evidence of method; any Baldwin synergy dollar is Acquiry interpretation and is not modelled here.

The weak version of the thesis is “add AI.” The investable version is redesigning quote, placement, renewal, claims, data and administrative workflows while protecting producer judgment and client relationships. Sequence’s public materials support the second version as intention. They do not support it as a priced Baldwin case.

Atlas and the BankSouth reference

BankSouth is Sequence’s first disclosed operating partnership, discussed here as a reference case for method, not as an asset in this transaction. Sequence has described a minority financial and hands-on operating investment in a $1.6 billion-asset community bank, and later reported that BankSouth’s loan origination process fell from nine stages to three, time from application to closing fell approximately 52%, and loan volume doubled with the same team.^[10][11] Those are company-reported outcomes. They describe the intended mechanism: reduce middle- and back-office friction so relationship professionals can support more volume.

They are not directly transferable. Baldwin is larger, more acquisitive, multi-line, carrier-dependent and distributed across more workflows and jurisdictions than a community bank. Producer relationships, carrier markets, placement workflows and benefits administration do not map one-for-one onto BankSouth’s processes. Useful operating questions at Baldwin would be cycle time from client data collection to market submission, rework rates, producer time spent on administration, renewal throughput, quote-to-bind conversion, carrier appetite-match accuracy, client retention, exception rates and margin lift net of technology and change costs. None of those Baldwin metrics have been published as an Atlas baseline. Until they are, BankSouth remains a method sample from a different operating system. Treating it as a Baldwin synergy case would be an Acquiry invention, and this article does not make that invention.

What remains speculative, stated once: any dollar quantum for Atlas at Baldwin, any headcount or producer-productivity target, and any timeline on which those effects would appear in organic growth or margin. The buyers have described the operating model. They have not priced it.

Acquiry interpretation

Acquiry’s view is that the buyers are underwriting an operating thesis, not a financial-engineering thesis. The entry multiple leaves limited room for a pure multiple-compression exit. Value has to come from organic recovery, CAC integration, Atlas-enabled productivity, or some combination of the three. Patient capital can fund that work through reporting cycles the public market would punish. It cannot substitute for producer retention or for a CAC integration that still has to land.

The immediately visible benefits are governance and time horizon. Private ownership can move capital and organizational attention without quarterly public-market signaling. Talent ownership can be widened and made more specific to performance. AI productivity, organic-growth recovery and margin expansion take longer and require operating evidence. Acquiry does not attach a dollar synergy estimate because the buyer has published none and the available process metrics do not support one.

On strategic logic, the buyer group fits the stated problem. DFO supplies patient capital. Sequence supplies engineering and an operating doctrine. Baldwin supplies scale, workflows, proprietary data, distribution and management continuity. The transaction gives all three a reason to remain aligned. The public record supports that intention. It does not support a modelled synergy number. Where this article distinguishes those two things, it is labelling disclosed strategy, reference-case evidence, and Acquiry interpretation as separate claims.

Baldwin published 20.0x LTM Adjusted EBITDA on $396 million. Financing is fully committed with no financing condition. Comparable broker deals print lower EBITDA-family multiples on different denominators.

Financing and capital structure

Baldwin says fully committed debt and DFO equity financing are in place and that the merger is not subject to a financing condition.^[2][4] That matters for closing risk: Baldwin shareholders are not underwriting a financing out. The 8-K says Parent has debt commitment letters and an equity commitment from DFO. It does not tell shareholders the cost of debt, the covenant package, or the funded leverage they will live with after close. The announcement does not split the equity cheque from the debt quantum. Existing debt may be repaid, refinanced or supplemented, and rollover reduces cash equity required. The announced net-debt bridge relative to trailing Adjusted EBITDA is therefore the disclosed arithmetic, not a forecast of funded closing leverage.^[22] Commitment without a term sheet is still commitment. It is not a credit opinion. Readers who need coupons, call protection, springing covenants or a sources-and-uses table will have to wait for later exhibits.

Fitch has argued that US insurance brokers remain cash-generative but that larger, debt-funded acquisitions raise leverage and interest-coverage questions as the cycle slows. Fitch notes that some sponsor-owned brokers operate at 8x to 10x EBITDA leverage or higher, sometimes with interest coverage below 1.5x.^[14] That is sector context, not a statement of Baldwin’s closing leverage. The filing confirms commitment. It does not confirm the post-close credit stats Fitch would want to see.

The 20.0x denominator

Baldwin published the take-private at approximately 20.0 times trailing-twelve-month Adjusted EBITDA of approximately $396 million. No synergy adjustment is stated.^[2] Adjusted EBITDA is company-defined. Readers comparing this print with other broker deals need to hold the denominator still. Gallagher agreed to pay $13.45 billion for AssuredPartners at 14.3x pro forma LTM EBITDAC gross, and presented 11.3x after a $1.0 billion deferred tax asset and $160 million of expected synergies.^[15] Baldwin’s own CAC combination was 7.9x including targeted full run-rate synergies.^[8]

Brown & Brown agreed to acquire Accession for $9.825 billion against $1.7 billion of revenue; no primary EBITDA multiple was disclosed.^[16] Marsh McLennan agreed to acquire McGriff for $7.75 billion cash against $1.3 billion LTM revenue.^[17] Those prints locate Baldwin inside a large-broker consolidation cycle. They do not price Atlas. They also do not use Baldwin’s Adjusted EBITDA definition. EBITDAC differs from Adjusted EBITDA. AssuredPartners’ net multiple gives credit for tax assets and synergies; Baldwin’s headline multiple does not. CAC uses a forward, synergy-inclusive denominator. Comparing a 20.0x LTM Adjusted EBITDA take-private with a 14.3x pro forma EBITDAC strategic acquisition is a reference exercise, not a verdict that Baldwin is “expensive” by a known number of turns on a common denominator. The defensible conclusion is only that Baldwin enters at a visibly higher published multiple.

US insurance brokerage remains a consolidating, cash-generative category. MarshBerry reports $83.3 billion of 2025 revenue across the Top 100 US brokers, with the top ten producing $58.5 billion, or 70%, and counted 854 announced US insurance brokerage transactions in 2025.^[12] PwC reports $29.6 billion of announced US insurance deal value across 191 disclosed transactions from 1 December 2025 through 31 May 2026. Its 2026 outlook identifies public-broker valuation compression, technology investment and AI uncertainty as live factors in distribution M&A.^[13] Scarcity at Baldwin’s scale supports strategic demand. It does not eliminate entry-price discipline. That industry backdrop is not a substitute for Baldwin’s own organic 2% print. A take-private at this size also removes a public comparable from the broker set. Remaining listed distributors will be read against a thinner tape; that is a market-structure consequence, not a Baldwin synergy.

Employee rollover is part of the capital structure, not a footnote. A significant minority of equity remaining with colleagues is how the buyers keep producers and specialists inside the outcome. The alignment benefit is clear: producers and executives can participate in value creation after close rather than receiving cash only. Exact elections, voting and board rights, dilution provisions, leaver terms and liquidity rights are not filed. The TRA amendment, capping final payments at $298,450,598 and then terminating the agreement, is a known cash use at close whose funding treatment relative to the published equity value is not isolated in the public exhibits.^[19][20]

Closing is targeted for Q1 2027. The merger agreement sets an initial outside date of 14 June 2027 and a regulatory extension to 14 September 2027. Execution risk sits in leverage, the CAC overlap and organic growth quality.

Transaction timeline

What still has to go right

Three execution points dominate. First, closing: a Baldwin shareholder vote after the proxy process, insurance-regulatory clearances in the jurisdictions that must approve a change of control, and the Q1 2027 window against the June and September 2027 outside dates. The merger agreement’s extension architecture identifies regulatory timing as the principal long-stop risk.^[4][5] Second, capital structure: the announced net-debt bridge is material relative to trailing Adjusted EBITDA; the funded stack, pricing and covenants are not yet public. Third, operations: three workstreams will overlap — finish CAC integration, close and finance the take-private, and accelerate enterprise-wide technology transformation. Each is manageable alone. Together they create sequencing risk, change fatigue, data-migration complexity and potential distraction for producers and client teams.^[6][8][10]

The correct operating principle is not maximum speed everywhere. It is a controlled sequence: protect client and carrier continuity, stabilize CAC data and governance, select high-friction workflows, prove outcomes in bounded domains, then scale. Any plan that attempts a whole-enterprise redesign before the operating baseline is stable is weak. Producer retention and colleague rollover are the human-capital hinge.

What success looks like, stated as a watchlist rather than a failure register:

• Proxy Statement Filing Target: Q4 2026Pending. File in the target window, subject to SEC clearance tracking deadlines.
• Shareholder votePending. Class A holders approve the merger after the proxy process.
• Target closing window: Q1 2027Targeted. Close inside the announced window and inside the contractual outside dates.
• Organic growth and Atlas evidenceExpected after close. Subsequent reported quarters show organic improvement; a first Atlas workflow is visible in Baldwin operations; producer retention holds through the ownership change.

On structure, closing certainty is credible. The price is confirmed, financing is committed, the deal is not subject to a financing condition, the board acted through an independent special committee, and the parent reverse fee exceeds the company fee. On valuation, the published LTM Adjusted EBITDA entry is full relative to the disclosed broker precedents, even after denominator caveats. Returns therefore depend on execution quality rather than purchase-price arbitrage. That is Acquiry interpretation, not a disclosed fact.^[5] Public Class A holders are being asked to accept a cash price that already embeds a large unaffected premium. Continuing colleagues are being asked to underwrite the operating programme from inside the capital structure. Both positions are coherent. They are not the same risk.

The parent termination fee and the absence of a financing condition reduce closing-risk asymmetry for Baldwin shareholders. They do not establish the economics of the post-close capital stack or the delivery of Atlas. Insurance-regulatory change-of-control filings, the proxy process and producer retention through close remain the live execution path. None of those items require a second risk register. They are the same three points stated above, with calendar labels attached.

Primary company and SEC disclosures rank above reporting. Calculations use disclosed inputs. Adjusted EBITDA remains Baldwin’s non-GAAP label.

1. 01Business Wire transaction announcement, 14 September 2026Primary
2. 02The Baldwin Group transaction announcementPrimary
3. 03Reuters, 14 September 2026Reported
4. 04Baldwin Form 8-K, filed 14 September 2026SEC
5. 05Agreement and Plan of MergerSEC
6. 06Baldwin Q2 2026 resultsPrimary
7. 07Baldwin FY2025 resultsPrimary
8. 08Baldwin and CAC Group combination announcementPrimary
9. 09Trevor Baldwin, “The Moment for Builders”Primary
10. 10Sequence Holdings, “Built to Refound”Primary
11. 11BankSouth partnership with Sequence HoldingsPrimary
12. 12MarshBerry, 2026 Top 100 insurance brokersIndustry
13. 13PwC 2026 US insurance deals outlookIndustry
14. 14Fitch, US insurance brokers and larger acquisitionsRatings
15. 15Gallagher / AssuredPartners announcementPrimary
16. 16Brown & Brown / Accession announcementPrimary
17. 17Marsh McLennan / McGriff announcementPrimary
18. 18Baldwin 2025 Form 10-KSEC
19. 19Voting, support and rollover agreement formSEC
20. 20Tax Receivable Agreement amendmentSEC
21. 21Yahoo Finance BWIN historical dataMarket data
22. 22Acquiry Deal Intelligence calculationsAcquiry

Method: Acquiry Deal Intelligence methodology. Acquiry was not engaged by any party. Nothing here is investment advice.